Biolexis, an American Fork, UT-based clinical stage AI-driven drug discovery company, raised $10M in Series A funding.
The round was led by Clarke Capital.
The company intends to use the funds to to expand its operations and accelerate the clinical development of its key drug candidates.
Led by CEO David Bearss, Biolexis Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. It discovers and develops novel clinical candidates through their proprietary MolecuLern AI-enabled drug discovery process.
Using its AI-driven MolecuLern™ process, Biolexis has 40 active programs in discovery and 10 pipeline programs in the IND-enabling stages of development. The process, which targets any class of protein to identify novel chemical entities (NCEs) with drug-like characteristics and real wet-lab data validation, reduces the discovery and development timeline from years to months.
FinSMEs
29/11/2023